

---

**From:** Richard Kahn [REDACTED]  
**Sent:** Tuesday, July 26, 2016 5:20 PM  
**To:** jeffrey E.  
**Subject:** Fwd: Buy VIX options for vol replacement trades

i reviewed trade idea as BAC and others on the street are =reparing for a choppy August general big picture thought =s that pain trade for short and mid term is higher - per amanda =nstitutional cash at 5.8% is highest since Nov 2001 long term there are concerns about 2017 projected =arnings

Spot Vix today per Amanda was 13.00  
amanda=said that you can adjust Aug 15/21 call spread to Sep 15/21 for =.00

if you =ike trade idea we can fine tune spread numbers and even do for \$0 cost =s proposed below: buy Aug 17 call sell Sep 24 call

please advise  
thank you

Richard Kahn  
HBRK Associates Inc.  
575 Lexington =venue 4th Floor  
New York, NY 10022  
[REDACTED]

Begin forwarded message:

From: =/b>"Ens, Amanda" [REDACTED]  
Subject: =/b>Buy VIX options =or vol replacement trades  
Date: =/b>July 26, 2016 at 12:13:18 PM =DT  
To: =/b>Richard Kahn [REDACTED]

We view buying VIX =all spreads as an attractive alternative to buying SPX or SPY put =preads. Would love to discuss in more detail if you have a few =inutes.

TRADE => buy VIX Aug 15 / 21 call spread for \$1.10 or buy VIX Aug 17 call, sell Sep 24 call for \$0 cost (ref =5.30 and 17.50)

The catalysts are =bundant enough to make the case to be long vol (Fed, BOJ, EU bank =tress test, ...) but the question is how to be long vol with the =heapest amount of premium spent.

1. Current positioning in the VIX =TPs (chart below) suggest that almost all of the \$100m vega that =as sold post-Brexit has been bought back. The total amount of vega now =tands at long \$180m, a very large number by any standard. Given =IX has its lowest expiry level since July 2014 last week at 11.62 and =hat the market has rallied 180pts (+9%) in a month, it does make sense =o buy some protection and be long some hedges.

2. However, the somewhat =rowded positioning in outright long VIX products is making owning vol a =ery expensive proposition over time. Last week July VIX futures had a =oll down of 1pt in just the last 24h of trading before it expired. The estimated roll down over a month is around 2.20 vol point right now, i.e. 14% of the value of the =urrent 1m VIX future. So while the direction is probably correct (long =ol), the vehicle being used might not be the most efficient. A very steep term structure should be utilized in a way =hat benefits a long vol position, not goes against it. VIX calendar =all spreads are one possible answer.

3. In addition, VVIX (implied VIX vol) has risen =0pts in 10 days, reflecting increased demand for outright VIX upside =alls (mostly strikes from 20 to 25, thus making VIX skew higher as =ell). At 91, VVIX is somewhat expensive for this level if VIX =utures and it advocates in favor of low premium trades in VIX (hence =preads rather than outright options).

Given the overall picture in the VIX market =urrently (ETPs long \$180m vega, steep VIX term structure, high VVIX), =e favor being long through August call spreads or Aug/Sep calendar call =preads:

- buy Aug 15 / 21 call spread for \$1.10, ref 15.30 (that is =alf the expected roll down of \$2.20 for being long 1m VIX future over 1 =onth);
- buy Aug 17 call, sell Sep 24 call for \$0 cost, ref 15.30 =nd 17.50 (the expected cost to buy back the Sep 24 call when Aug =expires should be around \$0.45 if VIX is at the same level as today and =he actual cost will depend on market conditions at the time).

#### DISCLAIMER FOR =ARKET COMMENTARY

This material =as prepared by Sales and Trading Personnel of Merrill Lynch. This =nformation is intended to provide informal, subjective comments =egarding the swaps market and is based on information from various publicly available sources. It does not and should not be =interpreted as fact, fundamental research or as constituting market, =nvestment or financial advice that may be relied upon. This =nformation is not a publication of Merrill Lynch Research (ML Research) and it has not been reviewed or approved by any employee of ML =esearch. Any summary of ML

Research notes and reports, and any reference or link to ML Research notes and reports, are qualified in their entirety by the views of ML Research. This information is based upon various sources believed to be reliable, but Merrill Lynch provides no guarantee, representation or warranty regarding the accuracy, completeness or timeliness of the information. Merrill Lynch will not be liable for any investment decision based in whole or in part on this information. The reader is required to make its own investment decisions, using as necessary the advice of independent advisors or consultants. Merrill Lynch does not make any guarantee as to the performance or success of any opinion or idea expressed in the information. This information does not constitute an offer, or a solicitation of an offer, to purchase or sell any securities or financial instruments. The material is intended for the sole use of the person or firm to whom it is provided and is for discussion purposes only. It is not intended for further dissemination in its present form and may not be disseminated to other parties. Merrill Lynch and its affiliates may trade for their own accounts in any of the securities of issuers mentioned herein or in related financial instruments, and from time-to-time may also perform or solicit investment banking or other services for, or from, any entity mentioned herein. ML Research Reports may be found at [www.mlx.ml.com](http://www.mlx.ml.com) <<http://www.mlx.ml.com/>> .

Generally, all OTC derivative transactions involve the risk of adverse or unanticipated market developments, risk of illiquidity and other risks. Any transaction terms are indicative only and are subject to change and any prices mentioned here are not bids or offers of Merrill Lynch to purchase or sell any securities or other financial instruments. swaps, options and other derivative transactions are not suitable for all investors. This material is not to be distributed to nor to be read by private clients. This brief statement does not disclose all of the risks and other significant aspects of entering into any particular transaction. Prior to undertaking any trade, you should discuss with your professional tax, ERISA, legal, accounting, regulatory or other adviser how such particular trade(s) may affect you.

In connection with any swap or over-the-counter ("OTC") derivative transaction, Merrill Lynch acts solely as a broker or in the capacity of an arm's length counterparty. Merrill Lynch is not acting as a fiduciary in respect of the investor and has no responsibility under the standards governing the conduct of fiduciaries, investment advisers or investment managers. Any information conveyed by Merrill Lynch in connection with this material or any transaction is and will be merely incidental to the provision of Merrill Lynch's services as a broker or role as counterparty and does not and will not serve as a primary basis of any investment decision by the investor. Merrill Lynch and its affiliates may trade for its own account, or for the accounts of others, in any of the securities of issuers mentioned herein or in related financial instruments, and from time-to-time may also perform or solicit investment banking or other services for, or from, any entity or person. Merrill Lynch does not provide tax, accounting or regulatory advice. Any tax statement contained herein were not intended or written to be used, and cannot be used for the purpose of avoiding U.S., federal, state or local tax penalties.

This material was prepared by Americas Equity Linked Sales and Trading Personnel of Merrill Lynch and is subject to the terms available at the following link:  
[http://www.ml.com/index.asp?id=7695\\_71373\\_71377\\_71380&typ=200.01](http://www.ml.com/index.asp?id=7695_71373_71377_71380&typ=200.01). Click here <[http://www.ml.com/email\\_terms/](http://www.ml.com/email_terms/)> for important additional terms relating to this e-mail. Merrill Lynch does not provide tax, accounting or regulatory advice. Any tax statements contained herein were not intended or written to be used, and cannot be used for the purpose of avoiding U.S., federal, state or local tax penalties. Please consult your advisor as to any tax, accounting or legal statements made herein.

Options involve risk and are not suitable for all investors. There is no guarantee that the option strategies promoted will accomplish the stated objectives. Options trading is considered speculative and may result in the loss of a portion of or all of your initial investment, and/or funds in excess of the principal invested. Prior to buying or selling an option, you should reference the Characteristics and Risks of Standardized Options, "Option Disclosure Document" (ODD). All clients must receive a copy of the ODD prior to conducting any option trades. Electronic copies of the ODD and any supplements are available on this website and the Option Clearing Corp website, located at the following link: <http://www.optionsclearing.com/about/publications/character-risks.jsp>.

Amanda Ens

Director =o:p class="">

Bank of America Merrill Lynch

Merrill Lynch, Pierce, Fenner & Smith Incorporated

One Bryant Park, 5th Floor, New York, NY 10036



The power of global connections™

---

This message, and any attachments, is for the intended recipient(s) only, may contain information that is privileged, confidential and/or proprietary and subject to important terms and conditions available at <http://www.bankofamerica.com/emaildisclaimer>. If you are not the intended recipient, please delete this message.

=

=